Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Corixa [CRXA] - cancer vaccines -- Ignore unavailable to you. Want to Upgrade?

To: sim1 who wrote (96)	9/12/2001 6:30:07 PM
From: sim1	Read Replies (1) \| Respond to of 222

IDEC Pharmaceuticals Brings Separate Patent Suits Against Corixa and Glaxo SmithKline Seeking Declaratory Judgment of Non-infringement and Invalidity SAN DIEGO--(BW HealthWire)--Sept. 11, 2001--IDEC Pharmaceuticals Corporation (NASDAQ: IDPH - news) announced that it filed two separate suits for Declaratory Judgment for patent non-infringement and invalidity. Both suits were filed in the federal district court in the Southern District of California. One suit is against Corixa Corporation, Coulter Pharmaceuticals, Inc., and the University of Michigan on six patents on products and processes relating to radioimmunotherapy. The second suit is against Glaxo SmithKline on two patents relating to cell culture media. The first lawsuit seeks a declaration that IDEC's ZEVALIN(TM) (ibritumomab tiuxetan) product and its use in the treatment of B-cell non-Hodgkin's lymphomas (NHL) do not infringe Corixa's issued U.S. patents. The second lawsuit seeks a declaration that IDEC's manufacture of ZEVALIN does not infringe Glaxo SmithKline's issued U.S. patents. IDEC has developed ZEVALIN, a radiolabeled antibody for the treatment of B-cell NHL. ZEVALIN delivers radiation directly to the cancerous cells by combining the cancer-killing ability of the radioisotope Yttrium-90 with the targeting power of a monoclonal antibody that binds to the CD20 antigen found on cancerous B-cells. Earlier today, the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) recommended approval of ZEVALIN for the proposed treatment of certain B-cell NHL.<snip>